Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Diaceutics Plc LSE:DXRX London Ordinary Share GB00BJQTGV64 ORD GBP0.002
  Price Change % Change Share Price Shares Traded Last Trade
  0.50 0.39% 128.50 17,803 08:00:00
Bid Price Offer Price High Price Low Price Open Price
127.00 130.00 128.50 128.50 128.50
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 12.70 -0.68 0.34 377.9 108
Last Trade Time Trade Type Trade Size Trade Price Currency
16:10:21 O 7,740 129.10 GBX

Diaceutics (DXRX) Latest News (4)

More Diaceutics News
Diaceutics Investors    Diaceutics Takeover Rumours

Diaceutics (DXRX) Discussions and Chat

Diaceutics Forums and Chat

Date Time Title Posts
24/6/202114:15DIACEUTICS SETS OUT STALL TO DOMINATE PRECISION MEDICINE TEST MARKET48

Add a New Thread

Diaceutics (DXRX) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2021-06-24 15:10:22129.107,7409,992.34O
2021-06-24 13:42:34128.776,9878,997.16O
2021-06-24 11:23:25128.771,1641,498.88O
2021-06-24 10:01:17128.771,0001,287.70O
2021-06-24 08:52:28128.80670862.96O
View all Diaceutics trades in real-time

Diaceutics (DXRX) Top Chat Posts

DateSubject
24/6/2021
09:20
Diaceutics Daily Update: Diaceutics Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker DXRX. The last closing price for Diaceutics was 128p.
Diaceutics Plc has a 4 week average price of 124p and a 12 week average price of 103p.
The 1 year high share price is 191p while the 1 year low share price is currently 99.50p.
There are currently 84,068,923 shares in issue and the average daily traded volume is 49,463 shares. The market capitalisation of Diaceutics Plc is £108,028,566.06.
24/6/2021
14:15
tomps2: Diaceutics Group CEO, Peter Keeling, and members of the senior management team provide an update on strategy, a demonstration of the DXRX SaaS platform and an expert industry panel discuss their views on the diagnostics market for precision medicine. Watch the video here: Https://www.piworld.co.uk/company-videos/diacuetics-aim-dxrx-2021-capital-markets-day/ Or listen to the Podcast here: Https://piworld.podbean.com/e/diacuetics-aim-dxrx-2021-capital-markets-day/
16/6/2021
10:02
tomps2: Diaceutics #DXRX Capital Markets Day 1pm today 16.6.21. This will include: DXRX platform demo, views from an expert industry panel & strategic update from management. To attend contact: diaceutics@almapr.co.uk
20/5/2021
14:54
melloteam: Just to let shareholders and prospective investors know that Diaceutics, ANGLE plc, Inspiration Healthcare Group plc, Polarean Imaging plc and IBT will be presenting at Mello Events’ Healthcare webinar on the 25th May at 5:30pm-9:30pm. The webinar will also include the latest insights and analysis from investment managers, research professionals, analysts and experienced investors. If you are a shareholder and you would like a ticket to the Healthcare event, please use the code SHVIP75 to receive 75% off your ticket. Https://melloevents.com/investingoodhealth/ Additionally, on the 24th May, The Property Franchise Group PLC and Samarkand will be presenting at the MELLOMonday webinar event on 24th May at 6pm-9:30pm. There will also be special insights from Michael Taylor (@shiftingshares): Using technical analysis to find trades. There will be over 600 investors attending and these are very popular shows with company presentations, fund manager and investor interviews, and panel sessions including the popular Mello BASH (Buy, Avoid, Sell or Hold). If you purchase a ticket to MELLOMonday, you will automatically get sent a link to the healthcare event! Tickets are still available and if you would like one at half price then enter the code MMTADVFN50. Https://melloevents.com/mellomonday24thmay/.
07/4/2021
16:36
fillipe: DXRX - perky today! f
31/3/2021
14:17
gizmohican: share price is suffering!
15/3/2021
23:14
megasonic: Interesting to see a 20k buy (120p ask) after market closed and a 100k buy (122.5p ask) timed at 140pm but only appear after market close. Both buys were at significantly higher prices than the closing ask of 117p. So yeah, does look like some MM games going on.Given impact of pandemic on non-Covid treatments, the financial report looks pretty positive. These results were better than Board were anticipating back in September and seems like recently launched DXRX platform is performing well. Wouldn't be surprised if next few days were blue.
15/3/2021
14:44
scepticalinvestor: Reckon the MM are dropping bid to scare punters. The 50k trade was a buy at at that price imo
07/9/2020
15:24
74tom: It depends on your definition of 'soon', the price was £1 at the start of the year and they've since added 14m shares @ £1.45.. They had a clean slate from the IPO until today, now sentiment is negative we'll see the low free float work against them, in the same way it drove the price up in January. They IPO'd at 76p and it honestly wouldn't surprise me to see the price back down at those levels before any turnaround, so potentially another 40% downside at least.
06/7/2020
08:22
gizmohican: Share price shooting up must be a trading update coming soon, looking at when last years was released!
15/6/2020
17:55
cyberbub: Not only should that new money see them through till the end of 2021, but it appears that people have invested heavily, at a very small discount, in a company on a forward p/e of probably about 50.The only way I can explain it is if investors believe that the new 'Nexus' platform will really deliver a major step change in revenue... leading to a leveraged rocket in net profit, due to large central costs which may not increase that much. With a very high 77% gross profit margin, it does seem credible??If you consider Slater's PEG ratio, it's on a p/e of 50 now, but if profits were to grow at a (say) 100% rate for the next few years, it would be considered very good value on a PEG of 0.5.If DXRX capture say 25% of the medium-term $2bn global testing market = $500m, at say 70% margin = $350m = say conservatively £150m after tax. Nice recurring revenues usually get a p/e of 15 so the company could be on a £2.5bn market cap, or a 25-bagger from today.So... Can anyone who knows the market better then me explain why DXRX's offering is so good that (a) they can make 77% gross margin, and (b) they don't need to worry too much about competition and can capture a big chunk of the market?Thanks!NAI
Diaceutics share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
DXRX
Diaceutics
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210625 02:57:15